Expression of hMLH1 and hMSH2 proteins in pleomorphic adenoma of minor salivary glands: Relationship with clinical and histologic findings

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 108, Issue 2, 2009, Pages 227-236

  Tobón Arroyave, Sergio Iván ^a   Flórez Moreno, Gloria Amparo ^a   Jaramillo Cárdenas, Juan Fernando ^b   Arango Uribe, Juan David ^b   Isaza Guzmán, Diana María ^c   Rendón Henao, Javier ^d  

^a Faculty of Dentistry   (Colombia)

^b Oral and Maxillofacial Surgeon   (Colombia)

^c Department of Integrated Basic Studies   (Colombia)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MINOR SALIVA GLAND; MISMATCH REPAIR; PATHOLOGY; PHYSIOLOGY; PLEOMORPHIC ADENOMA; SALIVARY GLAND TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOMA, PLEOMORPHIC; ADOLESCENT; ADULT; AGED; CHILD; DNA MISMATCH REPAIR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS, MINOR; TUMOR MARKERS, BIOLOGICAL;

EID: 67650125224     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2009.02.033     Document Type: Article

References (57)

1. Renehan A., Gleave E.N., Hancock B.D., Smith P., and McGurk M. Long term follow up of over 1000 patients with salivary gland tumors treated in a single centre. Br J Surg 83 (1996) 1750-1754
2. Pinkston J.A., and Cole P. Incidence rates of salivary gland tumors: results from a population based study. Otolaryngol Head Neck Surg 120 (1999) 834-840
3. Eveson J.W., and Cawson R.A. Salivary gland tumors: a review of 2410 cases with particular reference to histological type, site, age and sex distribution. J Pathol 146 (1985) 51-58
4. Spiro R.H. Salivary neoplasms: overview of a 35 year experience with 2807 patients. Head Neck Surg 8 (1986) 177-184
5. Speight P.M., and Barrett A.W. Salivary gland tumors. Oral Dis 8 (2002) 229-240
6. Waldron C.A. Mixed tumor (pleomorphic adenoma) and myoepithelioma. In: Ellis G.L., Auclair P.L., and Gnepp D.R. (Eds). Surgical pathology of the salivary glands (1991), Saunders, Philadelphia 165-186
7. Ethunandan M., Pratt C.A., and Macpherson D.W. Changing frequency of parotid gland neoplasms-analysis of 560 tumors treated in a district general hospital. Ann R Coll Surg Engl 84 (2002) 1-6
8. In: Seifert G. (Ed). WHO international histological classification of tumors. In: Histological typing of salivary gland tumors (1991), Springer-Verlag, Berlin 29-30
9. Röijer E., Nordkvist A., Ström A.-K., Ryd W., Behrendt M., Bullerdiek J., et al. Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol 160 (2002) 433-440
10. Ethunandan M., Witton R., Hoffman G., Spedding A., and Brennan P.A. Atypical features in pleomorphic adenoma-a clinicopathologic study and implications for management. Int J Oral Maxillofac Surg 35 (2006) 608-612
11. Stennert E., Wittekindt C., Klussmann J.P., Arnold G., and Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: a prospective histopathological and immunohistochemical study. Laryngoscope 114 (2004) 158-163
12. Félix A., Rosa J.C., Fonseca I., Cidadão A., and Soares J. Pleomorphic adenoma and carcinoma ex pleomorphic adenoma: immunohistochemical demonstration of the association between tenascin expression and malignancy. Histopathology 45 (2004) 187-192
13. Said S., and Campana J. Myoepithelial carcinoma ex pleomorphic adenoma of salivary glands: a problematic diagnosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 (2005) 196-201
14. Genelhu M.C., Gobbi H., Soares F.A., Campos A.H., Ribeiro C.A., and Cassali G.D. Immunohistochemical expression of p63 in pleomorphic adenomas and carcinomas ex-pleomorphic adenomas of salivary glands. Oral Oncol 42 (2006) 154-160
15. Katori H., Nozawa A., and Tsukuda M. Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma. Auris Nasus Larynx 34 (2007) 79-84
16. Di Palma S., Skálová A., Vanìèek T., Simpson R.H.W., Stárek I., and Leivo I. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology 46 (2005) 144-152
17. Gnepp D.R., Brandwein-Gensler M.S., El-Naggar A.K., and Nagao T. Carcinoma ex pleomorphic adenoma. In: Barnes L., Eveson J.W., Reichart P., and Sidransky D. (Eds). World Health Organization Classification of tumors. Pathology and genetics of head and neck tumors (2005), IARC Press, Lyon 242-243
18. Tortolodo M.E., Luna M.A., and Batsakis J.G. Carcinomas ex-pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Arch Otolaryngol 110 (1984) 172-176
19. Auclair P.L., and Ellis G.L. Atypical features in salivary gland mixed tumors: their relationship to malignant transformation. Mod Pathol 9 (1996) 652-657
20. Eveson J.W., and Yeudall A. What is the evidence for the progression from benign to malignant pleomorphic adenoma?. In: McGurk M., and Renehan A. (Eds). Controversies in the management of salivary gland disease (2001), Oxford University Press, Oxford 105-113
21. Righi P.D., Li Y.Q., Deutsch M., McDonald J.S., Wilson K.M., Bejarano P., et al. The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland. Anticancer Res 14 (1994) 2253-2257
22. Costa-Rosa J., Fonseca I., Félix A., and Soares J. Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Histopathology 28 (1996) 247-252
23. El-Naggar A.K., Callender D., Coombes M.M., Hurr K., Luna M.A., and Batsakis J.G. Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model?. Genes Chromosomes Cancer 27 (2000) 162-168
24. Voz M.L., Mathys J., Hensen K., Pendeville H., Van Valckenborgh I., Van Huffel C., et al. Microarray screening for target genes of the proto-oncogene PLAG1. Oncogene 23 (2004) 179-191
25. Kolodner R. Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 10 (1996) 1433-1442
26. Modrich P., and Lahuer R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Ann Rev Biochem 65 (1996) 101-133
27. Umar A., and Kunkel T.A. DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem 238 (1996) 297-307
28. Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., et al. hMSH2 forms specific mispairs-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A 93 (1996) 13629-13634
29. Surtees J.A., and Alani E. Mismatch repair factor MSH2-MSH3 binds and alters the conformation of branched DNA structures predicted to form during genetic recombination. J Mol Biol 360 (2006) 523-536
30. Bellacosa A., Cicchilliti L., Schepis F., Riccio A., Yeung A.T., Matsumoto Y., et al. MED1, a novel humam methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci U S A 96 (1999) 3969-3974
31. Harfe B.D., and Jinks-Robertson S. DNA mismatch repair and genetics instability. Annu Rev Genet 34 (2000) 359-399
32. Surtees J.A., Argueso J.L., and Alani E. Mismatch repair proteins: key regulators of genetic recombination. Cytogen Genome Res 107 (2004) 146-159
33. Chiaravalli A.M., Furlan D., Facco C., ·Tibiletti M.G., Dionigi A., Casati B., et al. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 438 (2001) 39-48
34. Eshleman J.R., and Markowitz S.D. Mismatch repair defects in human carcinogenesis. Hum Mol Genet 5 (1996) 1489-1494
35. Tsuda H., Akiyama F., Kurosumi M., Sakamoto G., Yamashiro K., Oyama T., et al. Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Protocol. Jpn J Cancer Res 91 (2000) 451-457
36. Lee J.H., Zhang X., Jung W.Y., Chae Y.S., and Kim I. DNA ploidy and c-Kit mutation in gastrointestinal stromal tumors. World J Gastroenterol 10 (2004) 3475-3479
37. Dardick I., van Nostrand A.W.P., and Phillips M.J. Histogenesis of salivary gland pleomorphic adenoma (mixed tumors) with an evaluation of the role of the myoepithelial cell. Hum Pathol 13 (1982) 62-64
38. Dardick I., van Nostrand A.W.P., Jeans M.T., Rippstein P., and Edwards V. Pleomorphic adenoma, I: ultrastructural organization of epithelial regions. Hum Pathol 14 (1983) 780-797
39. Poetsch M., Zimmermann A., Wolfy E., and Kleist B. Loss of heterozygosity occurs predominantly, but not exclusively, in the epithelial compartment of pleomorphic adenoma. Neoplasia 7 (2005) 688-695
40. Navarro R.d.e.L., Martins M.T., and de Araújo V.C. Maspin expression in normal and neoplastic salivary gland. J Oral Pathol Med 33 (2004) 435-440
41. Rigau V., Sebbagh N., Olschwang S., Paraf F., Mourra N., Parc Y., et al. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hmlh6 immunostaining. Arch Pathol Lab Med 127 (2003) 694-700
42. Zhu M., Li J., Zhang X., Liu X., Friedl W., Zhang Y., et al. Large genomic aberrations in MSH2 and MLH1 genes are frequent in Chinese colorectal cancer. Cancer Genet Cytogenet 160 (2005) 61-67
43. Murata H., Khattar N.H., Gu L., and Li G.-M. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett 223 (2005) 143-150
44. Staebler A., Lax S.F., and Ellenson L.H. Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability. Hum Pathol 31 (2000) 354-358
45. Cai K.Q., Albarracin C., Rosen D., Zhong R., Zheng W., Luthra R., et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 35 (2004) 552-559
46. Nunn J., Nagini S., Risk J.M., Prime W., Maloney P., Liloglou T., et al. Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck. Oral Oncol 39 (2003) 115-129
47. Castrilli G., Fabiano A., La Torre G., Marigo L., Piantelli C., Perfetti G., et al. Expression of hMSH2 and hMLH1 proteins of the human DNA mismatch repair system in salivary gland tumors. J Oral Pathol Med 31 (2002) 234-238
48. Thibodeau S.N., French A.J., Roche P.C., Cunningham J.M., Tester D.J., Lindor N.M., et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 56 (1996) 4836-4840
49. Shin K.-H., Shin J.-H., Kim J.-H., and Park J.-G. Mutational analysis of promoters of mismatch repair genes hMSH2 and hMLH1 in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: identification of three novel germ-line mutations in promoter of the hMSH2 gene. Cancer Res 62 (2002) 38-42
50. Leach F.S., Polyak K., Burrell M., Johnson K.A., Hill D., Dunlop M.G., et al. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 56 (1996) 235-240
51. Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., et al. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. J Clin Oncol 20 (2002) 1203-1208
52. Liu T., Tannegård P., Hackman P., Rubio C., Kressner U., Lindmark G., et al. Missense mutations in hMLH1 associated with colorectal cancer. Hum Genet 105 (1999) 437-441
53. Martins M.T., Altemani A., Freitas L., and Araújo V.C. Maspin expression in carcinoma ex pleomorphic adenoma. J Clin Pathol 58 (2005) 1311-1314
54. de Araújo V.C., Altemani A., Furuse C., Martins M.T., and de Araújo N.S. Immunoprofile of reactive salivary myoepithelial cells in intraductal areas of carcinoma ex-pleomorphic adenoma. Oral Oncol 42 (2006) 1011-1016
55. Lo Muzio L., Nocini P., Mignogna M.D., Pannone G., Staibano S., Procaccini M., et al. Immunocytochemical detection of hMSH2 and hMLH1 expression in oral SCC. Anticancer Res 19 (1999) 933-940
56. Sternlicht M.D., Kedeshian P., Shao Z.M., Safarians S., and Barsky S.H. The human myoepithelial cell is a natural tumor suppressor. Clin Cancer Res 3 (1997) 1949-1958
57. Sternlicht M.D., and Barsky S.H. The myoepithelial defense: a host defense against cancer. Med Hypotheses 48 (1997) 37-46